A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC).

Trial Profile

A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Dexamethasone; Fosaprepitant; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 26 May 2010 Primary endpoint 'Complete control of nausea and vomiting' and 'Patients with vomiting' has been met, according to a Merck media release.
    • 26 May 2010 Results have been published in Support Care Cancer 2010;18:423-431, according to a Merck media release.
    • 10 Nov 2009 Actual patient number (848) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top